News | November 08, 2024
Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Subscribe To Our Newsletter & Stay Updated
